Sumitomo Pharma

Press Release

November 2, 2026

Sumitomo Pharma Co., Ltd.

Notice Regarding the Execution of Definitive Agreement for the Succession of the GMP-Compliant Cell Processing CDMO Business by S-RACMO

S-RACMO Co., Ltd. (Head Office: Suita, Osaka; President and CEO: Atsushi Tsuchida; "S-RACMO"), a joint venture between Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; "Sumitomo Pharma") and Sumitomo Chemical Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director and President: Nobuaki Mito; "Sumitomo Chemical"), executed a Master Agreement with Takara Bio Inc. (Head Office: Kusatsu, Shiga; President and CEO: Tsuyoshi Miyamura; "Takara Bio") on November 2, 2026, as the definitive agreement for S-RACMO's succession of Takara Bio's GMP-compliant cell processing CDMO business (the "Business Succession"). Please refer to the attached document for further details.

Sumitomo Pharma has positioned regenerative and cellular medicine as one of its medium- to long-term growth areas and considers the Business Succession an important initiative toward expanding its regenerative and cellular medicine business.
Through the Business Succession, S-RACMO will take over personnel, assets, contract projects, and other items, and will combine the technologies and know-how in cellular immunotherapies cultivated by Takara Bio with S-RACMO's experience in the manufacturing of regenerative medicine and cell therapy products, thereby strengthening its contract manufacturing capabilities and business foundation.

Going forward, Sumitomo Pharma will continue to collaborate with Sumitomo Chemical, RACTHERA Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and CEO: Atsushi Ikeda), and S-RACMO, aiming to drive the growth of its regenerative and cellular medicine business and provide patients with new treatment options by bringing together the technologies and expertise of each company.

Contact:
Public Relations Group, Corporate Communications
Sumitomo Pharma Co., Ltd.
E-mail：prir@sumitomo-pharma.co.jp

Press Release

November 2, 2026

S-RACMO Co., Ltd.
Takara Bio, Inc.

Notice Regarding the Execution of Definitive Agreement for the Succession of the GMP-Compliant Cell Processing CDMO Business

S-RACMO Co., Ltd. (Head Office: Suita, Osaka; President and CEO: Atsushi Tsuchida; hereinafter "S-RACMO") and Takara Bio Inc. (Head Office: Kusatsu, Shiga; President and CEO: Tsuyoshi Miyamura; hereinafter "Takara Bio") entered into a basic agreement on July 21, 2026, regarding the succession of Takara Bio's GMP-compliant cell processing CDMO business (the "Business Succession"), and have continued discussions thereafter. We are pleased to announce that, on November 2, 2026, the parties executed a Master Agreement (the "Agreement") as the definitive agreement for the Business Succession.

Pursuant to the Agreement, S-RACMO and Takara Bio will proceed with the transfer of personnel, assets, contract projects, and other items related to this Business Succession. The closing of this transaction is targeted for January 1, 2027. Going forward, S-RACMO and Takara Bio will work together to ensure a smooth transition of the business and continuity of services to customers without disruption. As necessary, S-RACMO may lease a portion of Takara Bio's GMP manufacturing facilities and related premises and continue certain GMP-compliant cell processing services at those facilities for a transitional period.

Through this transaction, S-RACMO will further strengthen the manufacturing technologies, know-how, and specialized talent that form the foundation of its CDMO business, while also addressing a broader range of customer needs in Japan and overseas, including those related to cellular immunotherapies such as CAR-T cell therapy, thereby further expanding its business. Takara Bio will focus its CDMO business on key modalities, including nucleic acids/plasmids, proteins/enzymes and viral vectors, thereby optimizing its business portfolio and improving operational efficiency.
Furthermore, Takara Bio will supply viral vectors for gene transduction as raw materials for the gene-modified cells manufactured by S-RACMO. By leveraging their respective strengths in the gene and cell therapy field, the two companies will advance their collaboration and jointly maximize value for customers.

Atsushi Tsuchida, President and CEO of S-RACMO, commented: "We feel a profound sense of responsibility and great excitement as we take over the business that Takara Bio has cultivated over many years, while also looking forward to the new possibilities this

transaction will create. We will carefully carry forward Takara Bio's expertise and talented personnel in cellular immunotherapies, including CAR-T and TCR-T therapies, and combine them with S-RACMO's experience in iPS cells and commercial manufacturing. Through this combination of strengths, we will provide even greater value to our customers and contribute to bringing innovative treatments to patients in need as quickly as possible."

Tsuyoshi Miyamura, President and CEO of Takara Bio commented: "After carefully considering the future of our GMP-compliant cell processing CDMO business, we concluded that having the business continue under S-RACMO, which has extensive experience in commercial manufacturing, is the best way to ensure that our customers continue to receive value in the future. We are entrusting S-RACMO with the technologies and expertise we have developed, and we sincerely hope that the business will continue to grow and thrive in its new environment."

<Reference Information>

S-RACMO Co., Ltd.
News Release (dated July 21, 2026)
Notice Regarding the Signing of a Basic Agreement with Takara Bio on the Succession of the GMP-Compliant Cell Processing CDMO Business (Japanese only)

Takara Bio, Inc.
News Release (dated June 23, 2026)
Update on Discussions on the Succession of the GMP-Compliant Cell Processing CDMO Business

News Release (dated July 21, 2026)
Notice Regarding the Signing of a Basic Agreement on the Succession of the GMP-Compliant Cell Processing CDMO Business

For inquiries regarding this matter:

S-RACMO Co., Ltd.
Corporate Administration
ml-contact@s-racmo.co.jp

Takara Bio, Inc.
Public Relations and Sustainability Promotion Office
bio-ir@takara-bio.co.jp
Tel: 077-565-6970